[en] The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID) was founded in Paris in 1983 by Professor R Modigliani and colleagues. From the beginning, the aim of this international (France, Belgium and Switzerland), multicentre, French-speaking group was to address clinical questions raised by patients or physicians in their daily practice or the inflammatory bowel diseases community, by focusing on clinical research on treatments through randomised controlled trials, prospective cohorts and cross-sectional studies, quantifying the severity of various facets of the disease when necessary for these studies. This approach very innovative has contributed to the advancement of knowledge in inflammatory bowel diseases by publishing more than 120 original articles in peer-reviewed journals throughout the GETAID 40-year history, most of them in top publications in gastroenterology and hepatology journals. In this paper, we will see what GETAID's contribution has been over the last four decades, review reasons for success and forthcoming challenges.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Laharie, David; CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department , Université de Bordeaux , INSERM CIC 1401 , Bordeaux, France.
Vuitton, Lucine ; CHU de Besançon, Service de Gastroentérologie, UMR Inserm Right, Université de Franche-Comté, F-25030 Besançon, France.
Bourreille, Arnaud; Nantes Université, CHU de Nantes, Hôtel-Dieu, Hépato-Gastroentérologie, Institut des Maladies de l'Appareil Digestif, CIC Inserm 1413, F-44093 Nantes, France.
Bouhnik, Yoram; Paris IBD Center, Groupe Hospitalier Privé Ambroise Paré - Hartmann, Neuilly sur Seine, France.
Colombel, Jean-Frédéric; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Fumery, Mathurin ; Department of Gastroenterology, Amiens University hospital, and PeriTox, Université de Picardie, France.
Mailhat, Charlotte; GETAID. 50, rue Richer, 75009 Paris, France.
Mary, Jean-Yves; UMR-S- 1153 Inserm, Equipe ECSTRRA, Denis Diderot - Paris 7 University, Hôpital Saint-Louis, Paris, France.
Peyrin-Biroulet, Laurent; Department of Gastroenterology, Brabois Hospital, Nancy University, Nancy les Vandoeuvre-lès-Nancy, France.
Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn’s disease—based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:146–50.
Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut 2011;60:1178–81.
Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014;63:1607–16.
Modigliani R, Pieddeloup C, Hecketsweiler P, et al. Effect of levamisole on the prevention of developmental flare-ups in quiescent Crohn’s disease: a prospective multicenter controlled trial in 155 patients. Gastroenterol Clin Biol 1983;7:683–92.
Cortot A. Un modèle d’excellence scientifique française et d’amitié: le GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives). En hommage à Robert Modigliani. Hépato-Gastro Oncol Digest 2021;28:411–4.
Modigliani R, Mary JY. Reproducibility of colonoscopic findings in Crohn’s disease: a prospective multicenter study of interobserver variation. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci 1987;32:1370–9.
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983–9.
Lémann M, Mary JY, Colombel JF, et al; Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812–8.
Treton X, Bouhnik Y, Mary JY, et al; Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80–5.
Lemann M, Mary JY, Duclos B, et al; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054–61.
Laharie D, Bourreille A, Branche J, et al; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporine versus infliximab in acute severe colitis refractory to intravenous steroids: a randomized study. Lancet 2012;380:1909–15.
Laharie D, Bourreille A, Branche J, et al; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237–43.
Louis E, Mary JY, Vernier-Massouille G, et al; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on anti-metabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.e5; quiz e31.
Louis E, Resche-Rigon M, Laharie D, et al; GETAID and the SPARE-Biocycle Research Group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2023;8:215–27.
CosnesJ,BourrierA,LaharieD,etal;Grouped'EtudeThérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 2013;145:758–65.e2; quiz e14.
Bouhnik Y, Carbonnel F, Laharie D, et al; GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 2018;67:53–60.
Bouhnik Y, Pineton de Chambrun G, Lambert J, et al; MICA-GETAID Study Group. Adalimumab in biologic-naive patients with Crohn’s disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID. Clin Gastroenterol Hepatol 2023;21:3365–78.e5.
Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811–8.
Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647–53.
Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. Gut 1994;35:231–5.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, et al; I-CARE Collaborator Group. I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease. Clin Gastroenterol Hepatol 2023;21:771–88.e10.
D’Haens G, Vermeire S, Lambrecht G, et al; GETAID. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, or corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology 2018;154:1343–51.e1.
Amiot A, Seksik P, Meyer A, et al. Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe ulcerative colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial. UEGW 2023. OP211.
Carbonnel F, Colombel JF, Filippi J, et al; European Crohn’s and Colitis Organisation. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 2016;150:380–8.e4.
Amiot A, Viennot S, Uzzan M, et al. Recommandations de pratique pour le diagnostic et la prise en charge de la rectocolite hémorragique. Hépato-Gastro Oncol Digest 2022;29:441–77.
Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104:435–9.
Lerebours E, Bussel A, Modigliani R, et al. Treatment of Crohn’s disease by lymphocyte apheresis: a randomized controlled trial. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1994;107:357–61.
Florent C, Cortot A, Quandale P, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 1996;8:229–33.
Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688–93.
Colombel JF, Lémann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674–8.
Abitbol V, Mary JY, Roux C, et al; Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002;16:919–27.
Marteau P, Lémann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842–7.
Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease. Gastroenterology 2010;138:2275–81, 2281.e1.
Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2013;62:201–8.
Senéjoux A, Siproudhis L, Abramowitz L, et al; Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif [GETAID]. Fistula plug in fistulising ano-perineal Crohn’s disease: a randomised controlled trial. J Crohns Colitis 2016;10:141–8.
Moussata D, Allez M, Cazals-Hatem D, et al; the GETAID. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? Gut 2018;67:616–24.
Moreau J, Hammoudi N, Marthey L, et al; GETAID. Impact of an education programme on IBD patients’ skills: results of a randomised controlled multicentre study [ECIPE]. J Crohns Colitis 2021;15:432–40.
Caron B, Bouhnik Y, Laharie D, et al. Changing the course of Crohn’s disease with an early use of adalimumab: the CURE study from the GETAID. UEGW 2023. MP010.
Vuitton L, Poullenot F, Bouhnik Y, et al. Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial. ECCO 2024. P679.
Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215–9.
Beaugerie L, Brousse N, Bouvier AM, et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–25.
Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–42.
Bouhnik T, Le Berre C, Zappa M, et al. Development of a new index to assess small bowel inflammation severity in Crohn’s disease using magnetic resonance enterography. Crohns Colitis 360 2022;4:otac004.
Pariente B, Mary JY, Danese S, et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 2015;148:52–63.e3.
Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996;379:821–3.
Brouquet A, Maggiori L, Zerbib P, et al; GETAID Chirurgie Group. Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort. Ann Surg 2018;267:221–8.
Koudsi M, Martinez-Vinson C, Pigneur B, et al. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the Pediatric GETAID. J Pediatr Gastroenterol Nutr 2023;76:763–70.
Rivière P, D̕Haens G, Peyrin-Biroulet L, et al. Location but not severity of endoscopic lesions influences endoscopic remission rates in Crohn’s disease: a post hoc analysis of TAILORIX. Am J Gastroenterol 2021;116:134–41.
